A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE

Heather Payne(The Prostate Centre), Marco De Santis(Agostino Gemelli University Polyclinic), Serena Hilman(Weston General Hospital), Arzu Betul Duran, Angus Robinson(Royal Sussex County Hospital), Josep Gumà, M. Mira Flores(Hospital Universitari Arnau de Vilanova), Bernard Rappe(Onze Lieve Vrouwziekenhuis Hospital), A. Pranzo(Astellas Pharma (United Kingdom)), A. Serikoff(Honeywell (France)), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Louis-Marie Dourthe, S. Mallick(Hôpital Saint-Michel), Steven Joniau, B. Barón, Roberto Bordonaro(Ospedale Garibaldi)
European Urology Open Science
July 1, 2020
10.1016/s2666-1683(20)33170-0
Cited by 1

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649